Evidence map›Paper›PMID 40900276›Full record

ArticleBrain tumor pathology2026

Emergence of NEC features in corticotroph PitNETs: primary tumor, radiation-induced transformation, or metastasis?

Naoko Inoshita, Hiroshi Nishioka, Noriaki Fukuhara, Keita Tatsushima, Akira Takeshita, Yasuhiro Takeuchi, Yutaka Takazawa, Naotetsu Kanamoto, Shozo Yamada

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naoko InoshitaDepartment of Pathology, Toranomon Hospital, Tokyo, Japan. inonao3939@gmail.com.ORCID http://orcid.org/0000-0002-5459-3388
Hiroshi NishiokaDepartment of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan.
Noriaki FukuharaDepartment of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan.
Keita TatsushimaDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Akira TakeshitaDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Yasuhiro TakeuchiDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Yutaka TakazawaDepartment of Pathology, Toranomon Hospital, Tokyo, Japan.
Naotetsu KanamotoDepartment of Endocrinology, Osaka City General Hospital, Osaka, Japan.
Shozo YamadaHypothalamic Pituitary Center, Moriyama Memorial Hospital, Tokyo, Japan.

Funding

JSPS KAKANHI 19K07427
6 · The paper itself

Abstract

Pituitary neuroendocrine tumors (PitNETs) are generally benign, but a small subset may demonstrate aggressive behavior or undergo malignant transformation. Neuroendocrine carcinoma (NEC), defined as a high-grade, poorly differentiated neuroendocrine neoplasm, is extremely rare in the pituitary, and its existence as a primary entity remains controversial. We report two cases of corticotroph PitNETs in female patients with Cushing disease, in which NEC components emerged several years after radiotherapy. Case 1 presented as an invasive macroadenoma with cavernous sinus invasion, and Case 2 as a 5 mm microadenoma. In both cases, recurrent tumors developed following subsequent radiotherapy. NEC components exhibited marked nuclear pleomorphism, necrosis, elevated Ki-67 indices, diffuse p53 expression, and loss or reduction of ACTH and TPIT expression. In Case 2, faint TPIT expression and discontinuous tumor growth within the sella raised the possibility of a metastatic NEC to the pituitary could not be excluded. These cases highlight the emergence of NEC features in corticotroph PitNETs, most likely as a result of post-radiotherapy transformation. However, due to faint TPIT expression and an unusual tumor distribution in Case 2, the possibility of a primary NEC or metastatic neuroendocrine neoplasm from another organ cannot be definitively excluded.

Indexed as

ACTH-Secreting Pituitary AdenomaCarcinoma, NeuroendocrineNeoplasms, Radiation-InducedNeuroendocrine TumorsPituitary NeoplasmsAdenomaAdultCell Transformation, NeoplasticFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPituitary ACTH HypersecretionMalignant transformationMetastasisPitNETPituitary NECRadiotherapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.